Psyched Wellness (TSE:PSYC)
:PSYC
Top Page
Psyched Wellness
(PSYC)
Select Model
Select Model
Rating:43Neutral
Price Target:
C$0.01
▼(-50.00% Downside)
Action:ReiteratedDate:04/09/26
The score is primarily constrained by weak financial performance—large losses, worsening free cash flow burn, and shrinking equity—despite some revenue traction and no reported debt. Technicals add modest pressure with the stock trading below key moving averages, and valuation signals are not informative given the provided P/E and missing dividend yield.
Positive Factors
Product-level economics
Positive gross profit indicates the company’s Amanita muscaria formulations generate margin at the unit level. That suggests product unit economics can scale into profitability as fixed costs are absorbed, making margin expansion plausible with sustainable volume growth.
Negative Factors
Deep unprofitability
A structural mismatch exists between cost base and revenue: losses many multiples of sales indicate fixed and operating costs far exceed current scale. Without sustained revenue growth or cost restructuring, persistent deficits threaten long-term viability and require external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Product-level economics
Positive gross profit indicates the company’s Amanita muscaria formulations generate margin at the unit level. That suggests product unit economics can scale into profitability as fixed costs are absorbed, making margin expansion plausible with sustainable volume growth.
Read all positive factors
Psyched Wellness (PSYC) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$2.89M
Dividend YieldN/A
Average Volume (3M)81.03K
Price to Earnings (P/E)―
Beta (1Y)-0.29
Revenue Growth-41.18%
EPS Growth17.65%
CountryCA
Employees1,800
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)N/A
Shares Outstanding288,816,830
10 Day Avg. Volume36,477
30 Day Avg. Volume81,030
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.86
Price to Sales (P/S)12.22
P/FCF Ratio-1.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Psyched Wellness Business Overview & Revenue Model
Company Description
Psyched Wellness Ltd., a health supplements company, engages in the production and distribution of artisanal, medicinal mushrooms and associated consumer packaged goods. It offers Amanita Muscaria Tincture, which soothes the body, tackles physical...
How the Company Makes Money
Psyched Wellness generates revenue primarily through the sale of its Amanita muscaria–derived consumer wellness products under its own branding, including sales through direct-to-consumer channels (e.g., the company’s website) and through retail/w...
Psyched Wellness Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
24
Negative
| Breakdown | Nov 2025 | Feb 2025 | Feb 2024 | Feb 2023 | Feb 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 472.30K | 623.16K | 321.10K | 14.27K | 0.00 |
| Gross Profit | 189.79K | 241.89K | 155.71K | 7.54K | 0.00 |
| EBITDA | -5.08M | -4.52M | -3.32M | -4.29M | -65.14K |
| Net Income | -5.04M | -4.26M | -3.43M | -4.30M | -4.50M |
Balance Sheet | |||||
| Total Assets | 3.75M | 7.89M | 7.34M | 3.31M | 6.38M |
| Cash, Cash Equivalents and Short-Term Investments | 2.25M | 6.36M | 6.13M | 2.57M | 5.53M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 644.82K | 449.33K | 303.56K | 198.07K | 178.15K |
| Stockholders Equity | 3.10M | 7.44M | 7.03M | 3.11M | 6.20M |
Cash Flow | |||||
| Free Cash Flow | -4.05M | -3.11M | -3.11M | -3.18M | -3.04M |
| Operating Cash Flow | -4.05M | -3.10M | -3.03M | -3.09M | -3.01M |
| Investing Cash Flow | 0.00 | -2.78K | -44.84K | 126.99K | -28.58K |
| Financing Cash Flow | 0.00 | 3.39M | 6.64M | 0.00 | 6.51M |
Psyched Wellness Technical Analysis
Negative
0.02
Price Trends
0.01
Negative
0.01
Negative
0.02
Negative
Market Momentum
>-0.01
Positive
43.59
Neutral
0.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PSYC, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and above the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.59 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PSYC.
Psyched Wellness Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | C$1.40B | 22.55 | 12.97% | 2.67% | 11.25% | 58.21% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
45 Neutral | C$196.15M | -174.75 | -92.94% | ― | 212.16% | -46.40% | |
43 Neutral | C$2.89M | -1.15 | -70.53% | ― | -41.18% | 17.65% | |
42 Neutral | C$782.84K | -1.00 | -190.55% | ― | ― | -126.28% |
* Consumer Defensive Sector Average
TSE:PSYC
Psyched Wellness
0.01
>-0.01
-33.33%
TSE:BITE
Blender Bites
0.15
-0.01
-6.25%
TSE:JWEL
Jamieson Wellness Inc
33.92
3.74
12.39%
TSE:HBFG
Happy Belly Food Group
1.50
0.36
31.58%
TSE:MOOO.X
Happy Supplements Inc.
0.35
-0.81
-69.83%
TSE:CULT
Cult Food Science Corp.
0.32
-1.68
-84.00%
Psyched Wellness Corporate Events
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Psyched Wellness Raises Capital, Settles Debt in Shares and Tightens Ties With Lead Investor
Positive
Mar 20, 2026
Psyched Wellness has closed the first tranche of a non-brokered private placement, raising roughly C$860,000 through the issuance of common shares and warrants led by Gotham Green funds, and completed a shares-for-debt deal with Zerkalo that settl...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Psyched Wellness Secures Strategic Private Placement Led by Gotham Green
Positive
Mar 11, 2026
Psyched Wellness has entered into a non-binding term sheet with Gotham Green funds for a non-brokered private placement of common shares and warrants, aiming to raise up to C$1.72 million in two tranches, with the first tranche of about C$860,000 ...
Business Operations and StrategyProduct-Related Announcements
Psyched Wellness Sells Out First Run of Calmer and Ramps Up Production
Positive
Jan 15, 2026
Psyched Wellness has sold out the initial production run of its new double-strength relaxation product, Calmer, which is formulated with the company’s proprietary AME-1 extract and positioned as an enhanced version of its existing Calm offer...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.